Table 1 Patient demographic characteristics (intention-to-treat population)
|  | PF-06438179/GP1111 (n = 324) | Infliximab-EU (n = 326) | All patients (N = 650) |
|---|---|---|---|
Gender, n (%) | |||
 Female | 258 (79.4) | 264 (81.0) | 522 (80.3) |
 Male | 66 (20.4) | 62 (19.0) | 128 (19.7) |
Age, mean (SD), years | 52.8 (13.3) | 52.8 (12.9) | 52.8 (13.1) |
Weight, mean (SD), kg | 73.3 (19.8) | 74.2 (20.0) | 73.8 (19.9) |
Body mass index, mean (SD), kg/m2 | 27.2 (6.4) | 27.7 (7.0) | 27.4 (6.7) |
Race, n (%) | |||
 White | 257 (79.3) | 247 (75.8) | 504 (77.5) |
 Black | 5 (1.5) | 9 (2.8) | 14 (2.2) |
 Asian | 46 (14.2) | 45 (13.8) | 91 (14.0) |
 Other | 15 (4.6) | 25 (7.7) | 40 (6.2) |
 Unspecified | 1 (0.3) | 0 | 1 (0.2) |
Geographic region, n (%) | |||
 North American and Western Europe | 50 (15.4) | 51 (15.6) | 101 (15.5) |
 Japan | 24 (7.4) | 23 (7.1) | 47 (7.2) |
 South Korea | 4 (1.2) | 5 (1.5) | 9 (1.4) |
 Latin America | 22 (6.8) | 22 (6.7) | 44 (6.8) |
 Rest of the world | 224 (69.1) | 225 (69.0) | 449 (69.1) |